Upsized deal from Cannacord may explain lack of gain today
Mydecine Innovations Group Upsizes Previously Announced Bought Deal Author of the article:Business Wire Business Wire Publishing date:Jan 20, 2021 6 minutes ago Canaccord Genuity has agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 30,000,000 units of the Company (the Units) at a price of C$0.50 per Unit (the Issue Price) for aggregate gross proceeds to the Company of C$15,000,000 (the Offering). Each Unit will be comprised of one common share in the capital of the Company (a Common Share) and one Common Share purchase warrant (a Warrant). Each Warrant will be exercisable to acquire one Common Share (a Warrant Share) for a period of 36 months following the Closing Date at an exercise price of $0.70 per Warrant Share.